Goldman Sachs’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-1,905,276
| Closed | -$9.22M | – | 5641 |
|
|
2020
Q1 | $9.22M | Buy |
1,905,276
+551,588
| +41% | +$3.58M | ﹤0.01% | 2140 |
|
|
2019
Q4 | $14.4M | Sell |
1,353,688
-23,769
| -2% | -$236K | ﹤0.01% | 2138 |
|
|
2019
Q3 | $14.3M | Sell |
1,377,457
-97,196
| -7% | -$1.27M | ﹤0.01% | 2063 |
|
|
2019
Q2 | $22.6M | Buy |
1,474,653
+110,685
| +8% | +$1.6M | 0.01% | 1751 |
|
|
2019
Q1 | $17.5M | Buy |
1,363,968
+1,324,590
| +3,364% | +$15M | 0.01% | 1989 |
|
|
2018
Q4 | $374K | Buy |
39,378
+19,798
| +101% | +$257K | ﹤0.01% | 4530 |
|
|
2018
Q3 | $325K | Sell |
19,580
-4,003
| -17% | -$64.2K | ﹤0.01% | 4678 |
|
|
2018
Q2 | $379K | Buy |
23,583
+1,822
| +8% | +$32.5K | ﹤0.01% | 4668 |
|
|
2018
Q1 | $333K | Buy |
+21,761
| New | +$339K | ﹤0.01% | 4728 |
|
|
2017
Q4 | – | Sell |
-37,422
| Closed | -$415K | – | 6822 |
|
|
2017
Q3 | $415K | Buy |
+37,422
| New | +$352K | ﹤0.01% | 5231 |
|
|
2016
Q4 | – | Sell |
-12,158
| Closed | -$132K | – | 7187 |
|
|
2016
Q3 | $132K | Buy |
+12,158
| New | +$98.9K | ﹤0.01% | 6088 |
|
|
2016
Q2 | – | Sell |
-11,592
| Closed | -$54K | – | 7368 |
|
|
2016
Q1 | $54K | Sell |
11,592
-5,466
| -32% | -$26.7K | ﹤0.01% | 6389 |
|
|
2015
Q4 | $108K | Sell |
17,058
-449,418
| -96% | -$3.65M | ﹤0.01% | 6136 |
|
|
2015
Q3 | $4.12M | Buy |
466,476
+5,548
| +1% | +$58.2K | ﹤0.01% | 3055 |
|
|
2015
Q2 | $5.42M | Sell |
460,928
-871
| -0.2% | -$12.1K | ﹤0.01% | 2886 |
|
|
2015
Q1 | $6.68M | Sell |
461,799
-19,712
| -4% | -$302K | ﹤0.01% | 2627 |
|
|
2014
Q4 | $8.21M | Buy |
481,511
+185,094
| +62% | +$2.67M | ﹤0.01% | 2517 |
|
|
2014
Q3 | $3.69M | Sell |
296,417
-34,497
| -10% | -$425K | ﹤0.01% | 3327 |
|
|
2014
Q2 | $4.86M | Buy |
330,914
+75,888
| +30% | +$1.16M | ﹤0.01% | 3070 |
|
|
2014
Q1 | $5.19M | Buy |
255,026
+34,763
| +16% | +$844K | ﹤0.01% | 2978 |
|
|
2013
Q4 | $4.32M | Sell |
220,263
-590
| -0.3% | -$15.7K | ﹤0.01% | 3240 |
|
|
2013
Q3 | $10M | Buy |
220,853
+175,026
| +382% | +$5.71M | ﹤0.01% | 2251 |
|
|
2013
Q2 | $1.09M | Buy |
+45,827
| New | +$730K | ﹤0.01% | 4323 |
|
Goldman Sachs's STML Position: Q2 2020 in Review
Goldman Sachs sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 1,905,276 shares — an estimated $9.22M sold.
Goldman Sachs first reported a position in STML in Q2 2013 and held it in 23 quarters. The position peaked at $22.6M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Goldman Sachs reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Goldman Sachs sold 1,905,276 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $9.22M.
- Goldman Sachs first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 23 quarters.
- Goldman Sachs's Stemline Therapeutics, Inc. position peaked at $22.6M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.